The window for commenting on the FDA's draft guidance on pharma's use of Twitter and other social media slammed shut last week, leaving the agency with a stack of feedback to consider. Many of the respondents are unhappy with the draft, which was called unconstitutional and overbroad.
Chemisense is developing an updated air-quality monitor and correlating smartphone app that will identify areas with heavy pollutants and irritants for users, as well as crowdsource the data users collect.
With scholarly social network ResearchGate now adding 10,000 users a day to its network of 4.5 million researchers, the idea of a "Facebook for science" has finally taken off. But these numbers say nothing about whether people actually use the site and why, a shortcoming Nature has tried to fix by surveying thousands of researchers about their social media habits.
Apple released its newest operating system, iOS 8 beta 5, on Aug. 4. The system includes a number of health-related features such as icons for "Body Data" and "Data Exporting."
A Wall Street Journal feature this week on researchers' long-standing concerns about the consequences of patients talking about clinical trials online digs into how biopharma companies are tapping technology to counter concerns about unblinding and manipulating inclusion/exclusion criteria.
A wearable device for measuring exposure to ultraviolet light and a "smart" Kegel exercise aid recently created pages on Kickstarter requesting funders, highlighting the use of crowdfunding to back edgy new devices.
What's #FOGO? Hint: Many of us have it. Another hint: Pfizer wants people to talk about it.
The FDA may be having problems handing down its social media commandments. But it's playing enforcer just the same.
Having had a week to mull over the FDA's latest batch of social media guidance, some observers have concluded the agency is making a blunt statement to brand managers: Don't use Twitter.
Any brand managers eager to jump into Twitter as soon as the FDA gave the go-ahead? No such luck. Last week's social media guidance on risk disclosures may have cleared up some of the regulatory fog, but in this case, clarity isn't a positive.